A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, A N Phillips, S De Wit, M Ristola, J D Lundgren, J Grarup, O Kirk, EuroSIDA in EuroCOORD (Thomas Benfield, members), Thomas Benfield (Medlem af forfattergruppering)

5 Citationer (Scopus)

Abstrakt

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

OriginalsprogEngelsk
TidsskriftInfection
Vol/bind42
Udgave nummer4
Sider (fra-til)757-62
Antal sider6
ISSN0300-8126
DOI
StatusUdgivet - aug. 2014

Fingeraftryk

Dyk ned i forskningsemnerne om 'A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe'. Sammen danner de et unikt fingeraftryk.

Citationsformater